Australia Clears Kimberly-Clark's $40B Kenvue Acquisition with Divestments

Key Facts

1Australia's competition regulator approved Kimberly-Clark's $40 billion acquisition of Kenvue.

2The approval is conditional on the divestment of Kenvue's Carefree and Stayfree period care brands in Australia.

In a move reflecting heightened regulatory scrutiny over mega-mergers in the consumer goods sector, Australia's competition regulator has approved Kimberly-Clark's $40 billion acquisition of Kenvue. The approval is strictly conditional on the divestment of Kenvue's Carefree and Stayfree period care brands within the Australian market. This intervention aims to mitigate antitrust concerns and ensure that consumer choice remains protected following the massive consolidation.

This regulatory milestone comes as the consumer healthcare industry seeks operational efficiencies through large-scale M&A activity. Per market data, Kenvue (KVUE) shares closed at $18.88 on August 31, 2026, having traded between a day low of $18.83 and a high of $19.1 during that session. Clearance in a significant market like Australia moves the global deal closer to completion, despite the minor concessions required regarding specific brand assets.

Traders should watch for price stability around the $18.83 support level established at the close of August 31, 2026, as the merger progresses. While the recent economic calendar showed US Core PCE Price Index holding at 3.3% YoY as of August 26, the focus for KVUE remains on the execution of these mandated divestments and any subsequent filings regarding the final closing date of the transaction.